The latest price target for CG Oncology (NASDAQ:CGON) was reported by RBC Capital on December 6, 2024. The analyst firm set a price target for $66.00 expecting CGON to rise to within 12 months (a possible 130.20% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for CG Oncology (NASDAQ:CGON) was provided by RBC Capital, and CG Oncology reiterated their outperform rating.

The last upgrade for CG Oncology Inc happened on May 14, 2024 when Goldman Sachs raised their price target to $50. Goldman Sachs previously had a neutral for CG Oncology Inc.

There is no last downgrade for CG Oncology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CG Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CG Oncology was filed on December 6, 2024 so you should expect the next rating to be made available sometime around December 6, 2025.

While ratings are subjective and will change, the latest CG Oncology (CGON) rating was a reiterated with a price target of $66.00 to $66.00. The current price CG Oncology (CGON) is trading at is $28.67, which is out of the analyst’s predicted range.